⌘K
Loading ticker…
Lexicon Pharmaceuticals, Inc. · Healthcare · Pharmaceutical Products
As of 2026-06-26, Lexicon Pharmaceuticals, Inc. (LXRX) has a 3-month relative strength percentile of 91 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 79. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 6.5%, relative volume 17.08×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 91, Market Stance is mixed at 47, A/D rating A
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
LXRX is in a stage 2 uptrend, week 3. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 29.0% / 64.2%.
Strong relative strength with attention running hot versus its own recent norm. The trend is intact but well-noticed; elevated retail attention has historically been associated with softer forward returns. Context, not a call.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
LXRX is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $11M notional.
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $11M |
| VXFVanguard Extended Market ETF | 0.00% | $4M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LXRX Jan avg: 10.69% median: 9.84% win: 100% σ: 10.67% n: 4 2022-04-12 → 2026-05-29 | LXRX Feb avg: 13.21% median: 13.58% win: 75% σ: 19.77% n: 4 2022-04-12 → 2026-05-29 | LXRX Mar avg: -5.90% median: 1.25% win: 50% σ: 19.49% n: 4 2022-04-12 → 2026-05-29 | LXRX Apr avg: -0.71% median: -1.65% win: 40% σ: 37.10% n: 5 2022-04-12 → 2026-05-29 | LXRX May avg: 13.48% median: 10.39% win: 60% σ: 22.97% n: 5 2022-04-12 → 2026-05-29 | LXRX Jun avg: 6.06% median: 1.95% win: 50% σ: 33.72% n: 4 2022-04-12 → 2026-05-29 (current) | LXRX Jul avg: 15.70% median: 20.55% win: 75% σ: 20.57% n: 4 2022-04-12 → 2026-05-29 | LXRX Aug avg: -4.80% median: -5.81% win: 50% σ: 17.32% n: 4 2022-04-12 → 2026-05-29 | LXRX Sep avg: -8.97% median: -10.99% win: 25% σ: 24.39% n: 4 2022-04-12 → 2026-05-29 | LXRX Oct avg: 7.44% median: 7.99% win: 75% σ: 14.91% n: 4 2022-04-12 → 2026-05-29 | LXRX Nov avg: -17.54% median: -7.49% win: 25% σ: 28.58% n: 4 2022-04-12 → 2026-05-29 | LXRX Dec avg: 1.47% median: -9.43% win: 25% σ: 28.99% n: 4 2022-04-12 → 2026-05-29 |